

Cistus incanus: a natural source of antimicrobial metabolites

Anna De Filippis, Vincenzo D'Amelia, Veronica Folliero, Carla Zannella, Gianluigi Franci, Massimiliano Galdiero, Antonio Di Loria, Carmen Laezza, Simona Maria Monti, Anna Lisa Piccinelli, Rita Celano and Maria Manuela Rigano

QUERY SHEET

This page lists questions we have about your paper. The numbers displayed at left are hyperlinked to the location of the query in your paper.

The title and author names are listed on this sheet as they will be published, both on your paper and on the Table of Contents. Please review and ensure the information is correct and advise us if any changes need to be made. In addition, please review your paper as a whole for typographical and essential corrections.

Your PDF proof has been enabled so that you can comment on the proof directly using Adobe Acrobat. For further information on marking corrections using Acrobat, please visit <https://authorservices.taylorandfrancis.com/how-to-correct-proofs-with-adobe/>

The CrossRef database (www.crossref.org/) has been used to validate the references.

AUTHOR QUERIES

- Q1** Please provide the missing caption for Figures 3–6.
- Q2** The disclosure statement has been inserted. Please correct if this is inaccurate.
- Q3** Please provide complete details for (Sumner et al. 2007) in the reference list or delete the citation from the text.
- Q4** There is no mention of (Elshazly et al. 2023, Thabti et al. 2020) in the text. Please insert a citation in the text or delete the reference as appropriate.
- Q5** Please provide missing page range for the “Kubica et al., 2017” references list entry.
- Q6** Please provide missing volume number for the “Nickbakhsh et al., 2023” references list entry.



Cistus incanus: a natural source of antimicrobial metabolites

Anna De Filippis^{a*}, Vincenzo D'Amelia^{b,c*}, Veronica Folliero^a, Carla Zannella^a, Gianluigi Franci^d, Massimiliano Galdiero^a, Antonio Di Loria^{c,e}, Carmen Laezza^f, Simona Maria Monti^{c,g}, Anna Lisa Piccinelli^{h,i}, Rita Celano^{h,i} and Maria Manuela Rigano^{c,f}

^aDepartment of Experimental Medicine, section of Microbiology and Clinical Microbiology, University of Campania "L. Vanvitelli", Naples, Italy; ^bInstitute of Bioscience and BioResources, National Research Council, Portici, Italy; ^cImmunoveg s.r.l. c/o, Portici, Italy; ^dDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy; ^eDepartment of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy; ^fDepartment of Agricultural Sciences, University of Naples Federico II, Portici, Italy; ^gInstitute of Biostructures and Bioimaging, National Research Council, Naples, Italy; ^hDepartment of Pharmacy, University of Salerno, Fisciano, Italy; ⁱNational Biodiversity Future Center, NBFC, Palermo, Italy

ABSTRACT


The discovery of natural molecules with antimicrobial properties has become an urgent need for the global treatment of bacterium and virus infections. *Cistus incanus*, a Mediterranean shrub species, represents a valuable source of phytochemicals with an interesting wide-spectrum antimicrobial potential. In this study, we analysed the spectrum of molecules composing a commercial hydroalcoholic extract of *C. incanus* finding ellagitannins as the most abundant. The effect of the extract and its main constituents (gallic acid, ellagic acid and punicalin) was assessed as co-treatment during viral (HSV-1, HCoV-229E, SARS-CoV-2) and bacterial infection (*Staphylococcus aureus* and *Escherichia coli*) of cells and as pre-treatment before virus infections. The results indicated a remarkable antiviral activity of punicalin, against SARS-CoV-2, by pre-treating both the viral and the host cells, and a major sensitivity of *S. aureus* to the *C. incanus* extract compared to *E. coli*. The present study highlights broad antimicrobial potential of *C. incanus* extract.

ARTICLE HISTORY

Received 7 September 2023
Accepted 21 March 2024


KEYWORDS

Cistus incanus;
UHPLC-HRMS/MS;
ellagitannins; antiviral
and antibacterial activity



CONTACT Celano Rita ✉ rcelano@unisa.it; Rigano Maria Manuela ✉ mrignano@unina.it

*Co-first authors.

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/14786419.2024.2335353>.

© 2024 Informa UK Limited, trading as Taylor & Francis Group

44 **Q1 1. Introduction**

45 In the modern era, the pharmaceutical sector remains significantly inspired by
46 plant-derived compounds and plant extracts continue to be an important source of
47 promising drug candidates. A renewed scientific attention regards the potential use
48 of natural drugs against infectious diseases driven by the rapid spread of microbial
49 epidemics along with drug-resistant infectious diseases. This represent a global threat
50 to human health, even in developing countries (Limmathurotsakul et al. 2019; Rawson
51 et al. 2020). Current research trends in the field of natural drugs emphasise the eval-
52 uation of herbals (botanicals) used by diverse human populations in traditional medi-
53 cine. In particular, there is a growing interest for the herbal Chinese medicine, spurred
54 in part by the in 2015 Nobel Prize in medicine awarded to three scientists who
55 identified artemisinin from *Artemisia annua* as effective treatment against malaria.
56 Numerous papers are emerging that describe the biochemical characterisation and
57 bioactivity of extracts coming from herbs of the Chinese traditional medicine (Feng
58 et al. 2019; Malode et al. 2021; Pantharos et al. 2022). On the contrary, similar studies
59 on Western and Mediterranean herbals are still limited (Dziedziński et al. 2021;
60 Tomasella et al. 2022), although the practice of using wild plants for medicinal reasons
61 continues today in small rural communities of the Mediterranean region (Emre
62 et al. 2021).

63 Among Mediterranean herbals, *Cistus* is widely utilised by several communities,
64 and the use of its resin (labdanum) has been documented in southeastern Europe
65 for over 2,500 years (Barrajón-Catalán et al. 2011; Chovanec 2016). Also known as
66 rockroses, *Cistus* is a perennial shrub belonging to the Cistaceae family. The genus
67 *Cistus* includes more than 20 species of which *Cistus x incanus* L., *Cistus ladanifer* L.,
68 *Cistus monspeliensis*, and *Cistus salviifolius* are the most widely employed for healing
69 purposes (Kubica et al. 2017). Several *Cistus* species have been used in various forms
70 within the Mediterranean basin, as poultice, infusions, decoctions, and ointments
71 (Tomou et al. 2022). In Sardinia and Turkey local people used *Cistus* extracts as cure
72 for gastrointestinal disorders (Mastino et al. 2017; Fecka et al. 2020). In Morocco, seeds
73 of *Cistus* are consumed as appetiser food and thought to possess aphrodisiac qualities
74 (El Youbi et al. 2016). In addition, *Cistus* species have been also introduced in the
75 perfume industry given their aromatic properties (Nicoletti et al. 2015). In Spain, for
76 example, *Cistus* ointment is a noteworthy product in the cosmetic, employing it for
77 the treatment of skin infections and wound healing (Alarcón et al. 2015). *Cistus incanus*
78 is included in the BELFRIT botanical list of food supplements. The *folium* and *gummi*
79 are recommended as digestive and bronchial fluidifiers, while the *herba* is indicated
80 as an antioxidant and to enhance respiratory functions (Cousyn et al. 2013).

81 The metabolic repertoire and the related bioactivity of *Cistus* extracts have been
82 recently reviewed by Zalegh et al. and Tomou et al. (Zalegh et al. 2021; Tomou et al.
83 2022). Catechins, tannins, flavonols, diterpenes and sesquiterpenes are the main groups
84 of specialised metabolites detected within *Cistus* species (Venditti et al. 2015;
85 Gawel-Bęben et al. 2020; Zalegh et al. 2021). Glycosidic derivatives of kaempferol,
86 quercetin and myricetin, monomeric flavan-3-ols, proanthocyanidins, hydrolysable
87 tannins and simple phenolic acids (e.g. gallic, ellagic, gentisinic) were described as
88 typical for *Cistus* plants. Particularly, monoterpenes, sequiterpenes and labdane-type
89

90 diterpenes are the main compounds contained in leaves, stems and brown resin of
91 these plants (Fecka et al. 2020). Early studies described the efficiency of the diterpene
92 (+)-19-acetoxy-cis-clerodan-3-ene-15-oic acid, extracted from *C. monspeliensis* leaves,
93 against *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas*
94 *aeruginosa* (Kolocouris et al. 2001). More recently, Carev and co-workers (Carev et al.
95 2020) tested *C. salviifolius* and *C. creticus* aqueous extracts, enriched in
96 myricetin-3-hexoside and myricetin-rhamnoside, against fungi and bacteria, indicating
97 the major antimicrobial activity against the opportunistic yeast *Candida albicans* and
98 both Gram-positive and Gram-negative bacteria. Similarly, Salomé-Abarca and collab-
99 orators (Salomé-Abarca et al. 2020) tested extracts from 10 different ecotypes of *C.*
100 *monspeliensis* from Sardinia (Italy). They discovered their effectiveness against *Fusarium*
101 *oxysporum*, and authors hypothesised an additive or even a synergist activity of fla-
102 vonoids and diterpenes present in these extracts. The potential use of *Cistus* extract
103 has been suggested also against viruses (Zalegh et al. 2021). Already in 2007, Droebner
104 and collaborators (Ehrhardt et al. 2007) found the so-called CYSTUS052, a specific
105 extract from *C. incanus* rich in polymeric polyphenol, to be effective against influenza
106 A virus, without negative impact on systemic immune response suggesting the eligible
107 use of this remedy. About ten years later, *C. incanus* aqueous extracts have been
108 studied to contrast human immunodeficiency virus (HIV) with multidrug resistance
109 profile, and Filoviruses. The study showed an inhibition percentage higher than 80%,
110 proving how the extracts were able to block viral particles' attachment and inhibit
111 viral entry into host cells (Rebensburg et al. 2016). Considering this, *C. incanus* extracts
112 have been largely investigated allowing the identification of the massive presence of
113 polyphenols (Gawel-Bęben et al. 2020; Dziurka et al. 2021), which could play a role
114 in fighting not only viruses, but also bacteria. For this reason, *C. incanus* extract has
115 been considered also as an alternative means of overcoming antimicrobial resistance.

116 In this study, we examined the qualitative and quantitative profile of a commercial
117 hydroalcoholic extract of *C. incanus* and its antimicrobial properties against human
118 pathogens, including *Escherichia coli* and *Staphylococcus aureus*. Moreover, we exper-
119 imentally tested *C. incanus* extract against viruses belonging to the Coronaviridae and
120 Herpesviridae families. The main metabolites involved in the observed effects were
121 also identified. The goal of our work was to broaden current knowledge regarding
122 the role that *C. incanus* and the specialised metabolites characterising its extracts can
123 play against a wide spectrum of microbes and viruses, even towards the latest
124 SARS-CoV-2 coronavirus.

125 126 127 **2. Results and discussion**

128 **2.1. Chemical profile and cytotoxicity of *Cistus incanus* extract**

129
130 The increasing number of multidrug-resistant microorganisms represents a cogent
131 problem for human health worldwide, and this number will continue to increase.
132 There is the necessity of exploring new drugs that can represent alternatives in the
133 management of some serious infectious processes, starting from natural drugs pro-
134 vided by nature. *Cistus* genus is represented by different species of plant shrubs that
135 are part of the Mediterranean flora (Raimundo et al. 2018; Casadesús et al. 2021;

136 Coello et al. 2021). The taxonomy of the *Cistus* genus is intricate, presenting challenges
137 in the accurate identification of individual species. This complexity is exacerbated by
138 the polymorphism observed in both vegetative and generative organs, as well as the
139 potential hybridisation among closely related species, leading to the differentiation
140 of numerous subspecies (Guzmán and Vargas, 2005; Barrajon-Catalán et al. 2016; Fecka
141 et al. 2020). The focus of this study is a commercial extract of *Cistus x incanus*, a
142 hybrid derived from *Cistus albidus* and *Cistus crispus*, although the exact subspecies
143 remains unidentified. According to Starzec and colleagues, there are currently three
144 subspecies of *C. incanus*, namely *corsicus*, and *creticus*. Consequently, the issue of
145 synonymy is evident in *Cistus* species, where *Cistus incanus* is also referred to as *Cistus*
146 *creticus*, *Cistus villosus*, or pink or hairy rockrose (Viapiana et al. 2017). The difference
147 in biochemical composition is also dependent on the subspecies and can vary accord-
148 ing to the region (Starzec et al. 2023).

149 The available data on specialised metabolites of the genus *Cistus* indicates that
150 the main bioactive compounds are polyphenols. Specifically, compounds such as
151 flavonol glycosides, flavan-3-ols, proanthocyanidins, hydrolysable tannins and phenolic
152 acids (gallic and ellagic acids) were identified as typical for *Cistus* (Tomou et al. 2022).
153 In this study, we conducted a comprehensive analysis of the metabolic profile of a
154 *C. incanus* extract, aiming to identify putative molecules contributing to the extract's
155 bioactivity (Figure S1). The identified compounds are reported in Table 1 with their
156 detailed UHPLC-HRMS/MS data. In total, twenty-two major peaks were characterised,
157 and the identified compounds (confirmed by reference standards or tentatively identi-
158 fied by HRMS/MS data) were previously reported in the *Cistus* genus (Barrajon-Catalán
159 et al. 2011; Barros et al. 2013; Tomás-Menor et al. 2013; Gawel-Beben et al. 2020),
160 with the exception of the compounds **8**, **13** and **15**. According to the literature,
161 compounds **13** and **15** may be reaction artefacts, generated by the extraction process
162 (Venditti, 2020). Gallic acid (GA, **1**), its ethyl ester (**13**), ellagic acid (EA, **17**) and three
163 ellagitannins (**3**, **8** and **15**) resulted as the most abundant compounds of the inves-
164 tigated *C. incanus* extract (Table 1). Punicalin (**3**), the predominant ellagitannin, is
165 regarded as a distinctive ellagitannin of *Cistus* species, although its abundance strongly
166 depends on the genotype, origin, and environmental conditions (Tomás-Menor et al.
167 2013; Barrajon-Catalán et al. 2016). Ellagitannins are specialised metabolites commonly
168 found in certain berries (blackberries, strawberries, raspberries) (Van de Velde et al.
169 2018; Klewicka et al. 2020; Karlińska et al. 2021) and are also abundant in grapes and
170 pomegranate (Vignault et al. 2020; Suručić et al. 2021). The healing role of ellagitan-
171 nins has been recognised in several other plants used in Asia for medical purposes
172 such as *Camellia japonica*, *Cornus officinalis*, *Rosa rugosa*, and *Agrimonia Pilosa*, all of
173 which enriched in ellagitannins (Lipińska et al. 2014). Other polyphenols present in
174 the extract, albeit in markedly lower content, are flavan-3-ols (**5**, **9** and **11**) their related
175 dimers (**2**, **4**, **6** and **10**), the flavonols myricitrin (**16**), quercitrin (**21**) and myricetin
176 (**22**), and apigenin-6,8-di-C-glucoside (**14**). As minor compounds, three neolignans (-)
177 were tentatively identified in the studied extract based on their occurrence in *Cistus*
178 spp (Sadhu et al. 2006; Barrajon-Catalán et al. 2011) and HRMS/MS spectra (Table 1).
179 Before assessing the bioactivity of *C. incanus* extract and its main compounds, gallic
180 acid (GA), ellagic acid (EA) and punicalin (P), we evaluated the potential toxicity on
181 Vero cell monolayers by MTT test. Tested concentration did not affect cell viability,

Table 1. UHPLC-HRMS/MS data of compounds detected in *cistus incanus* extract.

N ^a	Compound	RT (min)	[M - H] ⁻ (m/z)	Molecular formula	Error (ppm)	Diagnostic product ions (m/z) ^b	L.I. ^c	mg/g ^d
1	gallic acid	1.69	169.0131	C ₇ H ₆ O ₅	-0.5	125.0232	1	15.3
2	(epi)galocatechin dimer	2.20	609.1253	C ₃₀ H ₂₆ O ₁₄	2.4	441.0827, 423.0724, 305.0668, 255.0299, 177.0188, 125.0233	2	
3	punicalin	2.61	781.0527	C ₃₄ H ₂₂ O ₂₂	1.1	600.9892, 392.9886, 300.9988, 298.9833, 270.9882	1	13.3
4	punicalin	2.77	781.0526	C ₃₄ H ₂₂ O ₂₂	0.9			
4	(epi)galocatechin dimer	3.39	609.1253	C ₃₀ H ₂₆ O ₁₄	2.3	441.0826, 423.0717, 305.0661, 255.0296, 177.0184, 125.0233	2	
5	(epi)galocatechin	4.82	305.0663	C ₁₅ H ₁₄ O ₇	2.4	261.0769, 219.0658, 137.0233, 125.0233 , 109.0283	2	
6	(epi)galocatechin-(epi)catechin	5.53	593.1305	C ₃₀ H ₂₆ O ₁₃	2.6	425.0873, 407.0771, 303.0506, 289.0717, 245.0817, 177.0184 , 125.0232, 109.0283	2	
7	hexoside of gallic acid ethyl ester	8.84	359.0986	C ₁₃ H ₂₀ O ₁₀	3.6	197.0448 , 182.0212, 153.0546, 138.0311	2	
8	valoneic acid dilactone	9.04	469.0048	C ₂₁ H ₁₀ O ₁₃	2.2	425.0152 , 407.0042, 379.0088, 335.0192, 299.9912	2	1.3
9	(epi)galocatechin	10.32	305.0666	C ₁₅ H ₁₄ O ₇	3.2	287.0559, 261.0769, 219.0658, 137.0233, 125.0233 , 109.0283	2	
10	(epi)catechin dimer	10.46	577.1352	C ₃₀ H ₂₆ O ₁₂	2.0	425.0882, 407.0767, 289.0716, 245.0815, 161.0234, 125.0232	2	
11	catechin	10.55	289.0713	C ₁₅ H ₁₄ O ₆	2.3	245.0814, 203.0706, 151.0390, 123.0440 , 125.0233, 109.0282	1	
12	roseoside	11.96	431.1919	C ₁₉ H ₃₀ O ₈	1.8	385.1866 , 223.1335, 205.1228, 179.0553, 161.0444, 153.0911	2	
13	gallic acid, ethyl ester	12.44	197.0445	C ₉ H ₁₀ O ₅	0.3	169.0132, 125.0233	2	2.9
14	apigenin-6-8-diC-glucoside (vicenin-2)	12.83	593.1514	C ₂₇ H ₃₀ O ₁₅	2.2	473.1113, 413.0844, 383.0770 , 353.0670, 325.0707	2	
15	valoneic acid bislactone, ethyl ester	14.49	497.0362	C ₂₃ H ₁₄ O ₁₃	2.3	450.9942	2	1.2
16	myricetin-3-deoxyhexose (myricitrin)	14.75	463.0878	C ₂₁ H ₂₀ O ₁₂	1.5	317.0290, 316.0222 , 287.0197, 271.0248, 178.9911, 151.0027	2	
17	ellagic acid	14.77	300.9987	C ₁₄ H ₆ O ₈	2.5	283.9961 , 229.0137, 185.0234, 163.0391	1	2.4
18	dihydrodehydrodiconiferil alcohol deoxyhexose	15.12	505.2077	C ₂₆ H ₃₄ O ₁₀	1.8	359.1499,	2	
19	guaiacylglycerol-O-4'-dihydroconiferil alcohol deoxyhexose	15.46	523.2179	C ₂₆ H ₃₆ O ₁₁	1.0	475.1972 , 329.1397, 327.1456, 195.0657, 165.0547, 150.0313, 149.0223	3	
20	guaiacylglycerol-O-4'-dihydroconiferil alcohol deoxyhexose	15.7	523.2181	C ₂₆ H ₃₆ O ₁₁	1.3	475.1974, 329.1385, 327.1447, 195.0656, 165.0548, 150.0312 , 149.0223	3	
21	quercetin-3-deoxyhexose (quercitrin)	16.07	447.0929	C ₂₁ H ₂₀ O ₁₁	1.5	301.0349, 300.0275 , 271.0249, 255.0297, 163.0025, 151.0026	2	
22	myricetin	16.61	317.0302	C ₁₅ H ₁₀ O ₈	3.1	271.0243 , 178.9977, 151.0027, 137.0233	1	

^aCompounds are numbered according to their elution order.^bIn bold the base peak of MS/MS spectrum.^cL.I.: level of identification, assigned according to Sumner (Sumner et al. 2007).^dResults are expressed as mg/g of dry extract.

228 except for a slight decrease at the highest tested concentrations (100 and
229 200 µg/mL) (Figure S2), confirming the safety of the extracts.

230

231

232 **2.2. Antiviral activity of *Cistus* extract**

233 *Cistus* extracts are considered natural remedies due to their attributed anti-inflammatory,
234 antitumoral, vasodilator, antispasmodic and antimicrobial properties (Barrajón-Catalán
235 et al. 2016). In this study, we analysed effects of *Cistus* extracts against different
236 human pathogenic viruses.


237 To date, *Cistus* extracts have been tested against a wide range of viruses, including
238 influenza virus (Droebner et al. 2007; Ehrhardt et al. 2007), human immunodeficiency
239 virus (HIV), Ebola virus (Rebensburg et al. 2016), and Dengue virus (Kuchta et al.
240 2020). These studies have demonstrated potent antiviral activity in the early phases
241 of viral infection. In this study, we tested the activity of *C. incanus* extract against
242 HSV-1 and coronaviruses, including the pandemic SARS-CoV-2. HSV-1 is responsible
243 for the common oral lesions, but it is rarely associated to severe manifestations, e.g.
244 neonatal herpes, keratitis, and encephalitis (de Mello et al. 2016). HSV-1 is an envel-
245 oped virus with a linear double-stranded DNA, and usually Latinises in the neuronal
246 ganglia causing recurrent events (de Mello et al. 2016). Some studies, reported this
247 virus as strongly related to the age of the patient, leading those aged ≥40 years to
248 be more affected than the rest of the population. Although it is predominantly trans-
249 mitted through oral shedding HSV-1 can be transmitted sexually, leading to genital
250 herpes. For instance, in Asia, it was demonstrated that this transmission route is
251 starting to play a significant role in the spread of infection (Kadhr et al. 2018).

252 Another enveloped virus, highly related to the seasonal cold, is the human coro-
253 navirus 229E (CoV-229E) that contains a linear single-stranded RNA (Kesheh et al. 2021).
254 Strictly associated is virus SARS-CoV-2, which shares many features with HCoV-229E,
255 but differently from it, caused and still is causing a huge number of deaths due to
256 serious upper respiratory failures (Kesheh et al. 2021). sCoVs cocirculate endemically
257 with other common respiratory viruses, and coinfections are very often observed; these
258 viruses were found to infect mainly people aged <1, 6-26, >64 years. In particular, the
259 data showed that CoV-229E affects patients according to sex differences, with males
260 being more prone to be infected than females (Nickbakhsh et al. 2023).

261 We investigated the mechanism of action of *C. incanus* extracts by using three
262 antiviral experimental schemes at non-cytotoxic concentrations against the viral
263 models: 1) co-treatment assay, each of the three viruses was incubated simultaneously
264 with *C. incanus* extract on Vero cell monolayer (Figures 1A and 3B,C); 2) virus
265 pre-treatment assay, *C. incanus* extract was incubated with the virus to test its antiviral
266 activity (Figures 1D and 3E,F) and 3) cell pre-treatment assay, *C. incanus* extract was
267 added on cells before viral infection (Figures 2G and 4H,I). As it can be observed in
268 Figure 1, the minimum concentration of *Cistus* extracts effective against virus varied
269 depending on the method and the virus studied. The best results for HSV-1 were
270 obtained after virus pre-treatments indicating that *C. incanus* extract interfered directly
271 with HSV-1 particles before they could interact with the cell. In fact, 100% of virus
272 inhibition was observed at a concentration of 3.12 µg/mL of extract (Figure 1D), rep-
273 resenting a four-fold more efficient effect compared to the same concentration used

274 in the co-treatment test (Figure 1A). Dell'Annunziata and collaborators explained that
 275 HSV-1 is characterised by a lipid envelope containing four glycosylated proteins pri-
 276 marily responsible for the fusion of the virus with the host cell membrane. Considering
 277 this, the diverse group of phytochemicals present in *C. incanus* extract may be capable
 278 of interfering with this fusion (Dell'Annunziata et al. 2022). A recent study further
 279 suggested that ellagitannins can be effective in inhibiting the binding between HSV-1
 280 and cell surface through virus inactivation (El-Aguel et al. 2022).

281 Positive results were observed for SARS-CoV-2 pre-treatment, and these effects
 282 were maintained when cells were simultaneously co-treated with the extract and the
 283 virus (Figure 1C). This result confirms what has recently been observed for CYSTUS
 284 PANDALIS®, where it has also been suggested that the peculiar polyphenol compo-
 285 sition of *Cistus x incanus* prevents virus from entering cells by reducing the binding
 286 between the receptor present on the surface of host cells (ACE2) and the S1 subunit
 287



315 **Figure 1.** (A–C) Co-treatment assay of *C. incanus* extract. Vero cell monolayers were treated with
 316 the extract (0.39–200 µg/mL) and infected with HSV-1 (A), HCoV-229E (B), or SARS-CoV-2 (C). D, E,
 317 F in the virus pre-treatment test, HSV-1 (D), HCoV-229E (E) or SARS-CoV-2 (F) were treated with the
 318 extract (0.39–200 µg/mL) and then diluted on the cell monolayer. (G), (H), and (I) in the cell
 319 pre-treatment test, vero cell monolayers were treated with the extract and then infected with
 HSV-1 (G), HCoV-229E (H) or SARS-CoV-2 (I). **** $p < 0.0001$; *** $p < 0.001$; ns: nonsignificant.

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365




Figure 2. Growth inhibition rate (%) of *S. aureus* exposure with (A) *C. incanus* extract (**** p value < 0.0001, ** p value = 0.002, * p value = 0.0475), (B) gallic acid (**** p value < 0.0001, ** p value = 0.0086, * p value = 0.0481), (C) ellagic acid (**** p value < 0.0001, * p value = 0.0139 and 0.456, ns: not significant), (D) punicalin (**** p value < 0.0001).

of the Spike protein or the receptor-binding domain of the virus (Traeder 2021). To attain 100% viral inhibition of HCoV-229E in either co-treatment or virus pre-treatment (Figures 1B and 3E), a higher concentration of the extract (a minimum 12.5 µg/mL) had to be used compared to SARS-CoV-2 and HSV-1 (3.12-6.25 µg/mL). This difference might arise from different binding affinities of phenolic compounds with protein components of the virus. The predominant effect of the *Cistus* compounds directly on the virus, rather than protecting cells, was further supported by the reduced inhibition of infectivity observed when cells were pre-treated with the extract (Figures 1G and 3H,I), and no inhibition ability was detected in post-treatment (i.e. *C. incanus* extract added to the cells already infected with the virus, data not shown). In particular, for HSV-1 a 100% viral inhibition was never achieved (Figure 1G), while for coronavirus this was attained only at the highest concentration tested (200 µg/mL) (Figures 1H and 3I).

To pinpoint the specific component of *C. incanus* extract with the highest antiviral potential, we conducted the same experimental schemes described for the total extract (except for the post-treatment test, because no viral inhibition was observed) using the three main constituents of investigated extract: gallic acid (GA), ellagic acid (EA) and punicalin (P) (Figure S3). In co-treatment and virus pre-treatments, the individual molecules exhibited a less potent effect, in terms of minimum concentration used, compared to the total extract (Figure S3A and Figure 4B– F). Among molecules, punicalin emerged as the most active compound against viruses. In some cases, i.e. virus pre-treatment against HSV-1 and SARS-CoV-2, its antiviral action was comparable to that of the total extract (Figure 1 and Figure S3). Molecular docking results obtained by Suručić et al. (Suručić et al. 2021) established the high affinity that punicalin,

366 identified in pomegranate (*Punica granatum* L.), has for the viral Spike protein and
367 the host cell proteins ACE2, TMPRSS2 and furin required by the SARS-CoV-2 for the
368 cell entry. In fact, both *in vitro* and *in silico* studies have identified in pomegranate
369 juice a potential beneficial food for alleviating COVID-19 side effects. This has been
370 attributed to its main components punicalin and punicalagin (Tito et al. 2021; Banihani
371 2022). In other studies, punicalin was found to cause a dramatic alteration of DNA
372 replication of hepatitis B virus, as it inhibits HBeAg (viral protein) and cccDNA in a
373 dose-dependent manner (Liu et al. 2016). These results may explain why *C. incanus*
374 antiviral potential is very effective during the virus pre-treatment assay against HSV-1,
375 a virus with a linear double-stranded DNA. Although punicalin was the most effective
376 molecule tested in most of the cases, its inhibitory activity did not completely overlap
377 with that reached when the full extract was used. This may be due to a limited
378 combined action of punicalin and other phytochemicals contained within *Cistus* extract.
379

380 2.3. Antibacterial activity of *Cistus* extract

382 To assess *C. incanus* extract antibacterial potential, we employed two different bacteria
383 strains, *E. coli* and *S. aureus*, representing Gram-negative and Gram-positive bacteria,
384 respectively. It has been reported that fruit extracts rich in ellagitannins are effective
385 against both Gram-positive and Gram-negative bacteria. For example, these have been
386 proven to inhibit *S. aureus*, *Pseudomonas aeruginosa*, *E. coli* growth, as well as on
387 certain Clostridia species (Li et al. 2015; Gullon et al. 2016; Baradaran Rahimi et al.
388 2020). In this study, *E. coli* and *S. aureus* were exposed to the extract at concentrations
389 ranging from 400 to 1.56 µg/mL for 20h, and the antibacterial effect was expressed
390 as percentage of growth inhibition compared to bacteria treated with the extract
391 solvent only (negative control, CTR-). A more potent antibacterial activity was observed
392 against *S. aureus* in all tested conditions compared to *E. coli*. A growth inhibition rate
393 of 35.9% was found after exposing of *S. aureus* to a concentration of 400 µg/mL of
394 total extract, which significantly decreased at concentration below 100 µg/mL (Figure
395 2A). The analyses of the single molecules again confirmed the inefficacy of *Cistus*
396 aqueous extract against *E. coli*, as the use of single molecules did not alter bacterial
397 growth (Figure S4B and Figure 6C,D). Concerning *S. aureus*, the highest antibacterial
398 effect was observed with gallic acid and punicalin, with MIC50 values of 40.2 and
399 75.4 µg/mL, respectively (Figures 2B and 5D). Consequently, the two single molecules
400 were even more efficient than the total extract (an average of 3-folds more efficient
401 for both molecules). In line with this, Liu et al. (Liu et al. 2017) demonstrated that
402 the expression of *ica* genes involved in the formation of poly-*N*-acetylglucosamine
403 polymer, part of Gram-positive peptidoglycan layer, was significantly downregulated
404 in a dose-dependent manner with increasing concentrations of gallic acid, establishing
405 the bactericidal potential of this compound against *S. aureus*. Punicalin also showed
406 an interesting antibacterial effect, and this is in line with what recently observed (Ravi
407 et al. 2019, Álvarez-Martínez et al. 2021) in *S. aureus*.

408 The proposed general molecular mechanism explaining how ellagitannins limit
409 bacterial growth lies in the reaction of these molecules with sulfhydryl groups of
410 proteins present in bacterial cell walls, resulting in toxicity (Singh et al. 2019). Hence,
411 we hypothesise that the variation in the effects on the two types of bacteria can be

412 simply explained by the structural difference in the cell membrane of Gram-positive
413 (*S. aureus*) and Gram-negative (*E. coli*) bacteria. Gram-negative bacteria possess an
414 outer peptidoglycan layer that acts more efficiently as barrier for antimicrobial agents.
415

416 3. Experimental

417 All details are provided in the [supplementary material](#).
418
419
420

421 4. Conclusion

422 In the current report, we provide new insights into the antiviral and antimicrobial
423 bioactivities of a commercial hydroalcoholic extract of *C. incanus* (*Cistus x incanus*).
424 Our findings demonstrate that gallic acid, ellagic acid and punicalin are significant
425 compounds exerting inhibitory effect against different pathogenic bacteria and virus
426 strains, including Gram-positive and Gram-negative bacteria, as well as coronavirus
427 and herpesviruses. To comprehensively understand the mechanisms underpinning the
428 bioactivity of *Cistus* extract, future investigations will expand the tests to include
429 pathogenic eukaryotic organisms, such as *C. albicans*. Additionally, these future anal-
430 yses will delve into more detailed aspects by integrating cellular and biochemical
431 analyses. The current results not only reinforce the traditional use of Mediterranean
432 medicinal plants for antiviral and antimicrobial purposes, but also highlight *Cistus* as
433 a potential neglected crop for bioactive compound production.
434
435

436 Acknowledgments

437 This manuscript reflects only the authors' views and opinions, neither the European Union nor
438 the European Commission can be considered responsible for them. We would like to thank
439 Revitalconcept scs for providing us with the material.
440

441 Disclosure statement

442 **Q2** No potential conflict of interest was reported by the author(s).
443
444
445

446 Funding

447 Project funded by National Recovery and Resilience Plan (NRRP), Mission 4 Component 2
448 Investment 1.3 - Call for proposals No. 341 of 15 March 2022 of Italian Ministry of University and
449 Research funded by the European Union – Next GenerationEU- Award number: Project code
450 PE00000003, Concession Decree No. 1550 of 11 October 2022 adopted by the Italian Ministry of
451 University and Research, CUP D93C22000890001, Project title 'ON Foods - Research and innova-
452 tion network on food and nutrition Sustainability, Safety and Security – Working ON Foods';
453 Centro Nazionale 5 'National Biodiversity Future Center'; Project code CN00000033, topic
454 'Bio-diversità', under the Piano Nazionale di Ripresa e Resilienza (PNRR)-Missione 4, Componente
455 2 'Dalla Ricerca all'Impresa' Investimento 1.4 'Potenziamento strutture di ricerca e creazione di
456 "campioni nazionali di R&S" on some Key Enabling Technologies'. Funded by FOE-2021 DBA.
457 AD005.225.

References

- 458
459 Alarcón R, Pardo-de-Santayana M, Priestley C, Morales R, Heinrich M. 2015. Medicinal and local
460 food plants in the south of Alava (Basque Country, Spain). *J Ethnopharmacol.* 176:207–224.
461 doi:10.1016/j.jep.2015.10.022.
- 462 Álvarez-Martínez FJ, Barrajón-Catalán E, Herranz-López M, Micol V. 2021. Antibacterial plant
463 compounds, extracts and essential oils: an updated review on their effects and putative
464 mechanisms of action. *Phytomedicine.* 90:153626. doi:10.1016/j.phymed.2021.153626.
- 465 Banihani SA. 2022. Possible beneficial effects of fresh pomegranate juice in SARS-CoV-2 infec-
466 tion conditions. *J Nutr Metab.* 2022:5134560–5134567. doi:10.1155/2022/5134560.
- 466 Baradaran Rahimi V, Ghadiri M, Ramezani M, Askari VR. 2020. Antiinflammatory and anti-cancer
467 activities of pomegranate and its constituent, ellagic acid: evidence from cellular, animal,
468 and clinical studies. *Phytother Res.* 34(4):685–720. doi:10.1002/ptr.6565.
- 469 Barrajón-Catalán E, Fernández-Arroyo S, Roldán C, Guillén E, Saura D, Segura-Carretero A, Micol
470 V. 2011. A systematic study of the polyphenolic composition of aqueous extracts deriving
471 from several *Cistus* genus species: evolutionary relationship. *Phytochem Anal.* 22(4):303–312.
472 doi:10.1002/pca.1281.
- 472 Barrajón-Catalán E, Tomás-Menor L, Morales-Soto A, Bruñá NM, López DS, Segura-Carretero A,
473 Micol V. 2016. Rockroses (*Cistus* sp.) oils. In *Essential oils in food preservation, flavor and*
474 *safety.* [place unknown]: Elsevier; p. 649–658.
- 475 Barros L, Alves CT, Dueñas M, Silva S, Oliveira R, Carvalho AM, Henriques M, Santos-Buelga C,
476 Ferreira ICFR. 2013. Characterization of phenolic compounds in wild medicinal flowers from
477 Portugal by HPLC–DAD–ESI/MS and evaluation of antifungal properties. *Ind Crops Prod.*
478 44:104–110. doi:10.1016/j.indcrop.2012.11.003.
- 478 Carev I, Maravić A, Ilić N, Čikeš Čulić V, Politeo O, Zorić Z, Radan M. 2020. UPLC-MS/MS phy-
479 tochemical analysis of two croatian *Cistus* species and their biological activity. *Life.* 10(7):112.
480 doi:10.3390/life10070112.
- 481 Casadesús A, Bouchikh R, Pérez-Llorca M, Munné-Bosch S. 2021. Linking jasmonates with vita-
482 min E accumulation in plants: a case study in the Mediterranean shrub *Cistus albidus* L.
483 *Planta.* 253(2):36. doi:10.1007/s00425-021-03570-y.
- 483 Chovanec Z. 2016. Making sense of ancient scents: documenting the use of perfumed sub-
484 stances in ancient Cyprus. *Anc Cyprus Today* :207–217.
- 485 Coello AJ, Fernández-Mazuecos M, García-Verdugo C, Vargas P. 2021. Phylogeographic sam-
486 pling guided by species distribution modeling reveals the quaternary history of the
487 Mediterranean–Canarian *Cistus monspeliensis* (Cistaceae). *J Syst Evol.* 59(2):262–277.
488 doi:10.1111/jse.12570.
- 488 Cousyn G, Dalfrà S, Scarpa B, Geelen J. 2013. Project BELFRIT-harmonizing the use of plants in
489 food supplements in the European Union: Belgium, France and Italy-A first step. *Eur Food*
490 *Feed L Rev.* 8:187.
- 491 Dell’Annunziata F, Sellitto C, Franci G, Marcotullio MC, Piovani A, Della Marca R, Folliero
492 V, Galdiero M, Filippelli A, Conti V, et al. 2022. Antiviral activity of *Ficus rubiginosa* leaf
493 extracts against HSV-1, HCoV-229E and PV-1. *Viruses.* 14(10):2257. doi:10.3390/v14102257.
- 493 Droebner K, Ehrhardt C, Poetter A, Ludwig S, Planz O. 2007. CYSTUS052, a polyphenol-rich
494 plant extract, exerts anti-influenza virus activity in mice. *Antiviral Res.* 76(1):1–10. doi:10.1016/j.
495 *antiviral.*2007.04.001.
- 496 Dziędziński M, Kobus-Cisowska J, Stachowiak B. 2021. Pinus species as prospective reserves of
497 bioactive compounds with potential use in functional food—current state of knowledge.
498 *Plants.* 10(7):1306. doi:10.3390/plants10071306.
- 498 Dziurka M, Kubica P, Kwiecień I, Biesaga-Kościelniak J, Ekiert H, Abdelmohsen SAM, Al-Harbi FF,
499 El-Ansary DO, Elansary HO, Szopa A. 2021. In vitro cultures of some medicinal plant species
500 (*Cistus incanus*, *Verbena officinalis*, *Scutellaria lateriflora*, and *Scutellaria baicalensis*) as a
501 rich potential source of antioxidants—evaluation by CUPRAC and QUENCHER-CUPRAC assays.
502 *Plants.* 10(3):454. doi:10.3390/plants10030454.
- 503

- 504 Ehrhardt C, Hrinčius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M,
505 Planz O, Ludwig S. 2007. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza
506 virus activity in cell culture without toxic side effects or the tendency to induce viral resis-
507 tance. *Antiviral Res.* 76(1):38–47. doi:10.1016/j.antiviral.2007.05.002.
- 508 El-Aguel A, Pennisi R, Smeriglio A, Kallel I, Tamburello MP, D'Arrigo M, Barreca D, Gargouri A,
509 Trombetta D, Mandalari G, et al. 2022. *Punica granatum* peel and leaf extracts as promising
510 strategies for HSV-1 treatment. *Viruses.* 14(12):2639. doi:10.3390/v14122639.
- 511 Elshazly EH, Nasr A, Elnosary ME, Gouda GA, Mohamed H, Song Y. 2023. Identifying the
512 anti-MERS-CoV and anti-HcoV-229E potential drugs from the *Ginkgo biloba* leaves extract
513 and its eco-friendly synthesis of silver nanoparticles. *Molecules.* 28(3):1375. doi:10.3390/
514 *molecules28031375*.
- 515 El Youbi AEH, El Mansouri L, Boukhira S, Daoudi A, Bousta D. 2016. In vivo anti-inflammatory
516 and analgesic effects of aqueous extract of *Cistus ladanifer* L. from Morocco. *Am J Ther.*
517 23(6):e1554–e1559. doi:10.1097/MJT.0000000000000419.
- 518 Emre G, Dogan A, Haznedaroglu MZ, Senkardes I, Ulger M, Satioglu A, Can Emmez B, Tugay
519 O. 2021. An ethnobotanical study of medicinal plants in Mersin (Turkey). *Front Pharmacol.*
520 12:664500. doi:10.3389/fphar.2021.664500.
- 521 Fecka I, Włodarczyk M, Starzec A. 2020. Isolation and structure elucidation of cistus: a new
522 ellagitannin from *Cistus x incanus* L. leaves. *Ind Crops Prod.* 158:112971. doi:10.1016/j.ind-
523 *crop.2020.112971*.
- 524 Feng L, Tian X, Yu Z, Zhao X, Sun C, Cui J, Ning J, Wang C, Zhang B, Ma X. 2019. A two-photon
525 ratiometric fluorescent probe for imaging and quantitative analysis of botanic glucosyltrans-
526 ferase: a key enzyme for the biosynthesis of bioactive glycosides. *Sensors Actuators B Chem.*
527 282:112–121. doi:10.1016/j.snb.2018.11.045.
- 528 Gaweł-Bęben K, Kukula-Koch W, Hoian U, Czop M, Strzępek-Gomółka M, Antosiewicz B. 2020.
529 Characterization of *Cistus x incanus* L. and *Cistus ladanifer* L. extracts as potential multifunc-
530 tional antioxidant ingredients for skin protecting cosmetics. *Antioxidants.* 9(3):202. doi:10.3390/
531 *antiox9030202*.
- 532 Gullon B, Pintado ME, Pérez-Álvarez JA, Viuda-Martos M. 2016. Assessment of polyphenolic
533 profile and antibacterial activity of pomegranate peel (*Punica granatum*) flour obtained from
534 co-product of juice extraction. *Food Control.* 59:94–98. doi:10.1016/j.foodcont.2015.05.025.
- 535 Guzmán B, Vargas P. 2005. Systematics, character evolution, and biogeography of *Cistus* L.
536 (*Cistaceae*) based on ITS, trnL-trnF, and matK sequences. *Mol Phylogenet Evol.* 37(3):644–660.
537 doi:10.1016/j.ympev.2005.04.026.
- 538 Kadhr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ. 2018. The
539 Epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and
540 meta-regressions. *Clin Infect Dis.* 68(5):757–772.
- 541 Karlińska E, Masny A, Cieślak M, Macierzyński J, Pecio Ł, Stochmal A, Kosmala M. 2021. Ellagitannins
542 in roots, leaves, and fruits of strawberry (*Fragaria x ananassa* Duch.) vary with developmental
543 stage and cultivar. *Sci Hortic (Amsterdam).* 275:109665. doi:10.1016/j.scienta.2020.109665.
- 544 Kesheh MM, Hosseini P, Soltani S, Zandi M, De Mello CPP, Bloom DC, Paixao ICNP, Yang H, Rao
545 Z. 2021. Structural biology of SARS-CoV-2 and implications for therapeutic development.
546 *Antivir Ther.* 21(2):e2282.
- 547 Klewicka E, Sójka M, Ścieszka S, Klewicki R, Milczarek A, Lipińska L, Kołodziejczyk K. 2020. The
548 antimycotic effect of ellagitannins from raspberry (*Rubus idaeus* L.) on *Alternaria alternata*
549 ŁOCK 0409. *Eur Food Res Technol.* 246(7):1341–1349. doi:10.1007/s00217-020-03493-0.
- 550 Kolocouris A, Mavromoustakos T, Demetzos C, Terzis A, Grdadolnik SG. 2001. Structure eluci-
551 dation and conformational properties of a novel bioactive clerodane diterpene using a
552 combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
553 *Bioorg Med Chem Lett.* 11(6):837–840. doi:10.1016/S0960-894X(01)00072-5.
- 554 Kubica P, Szopa A, Ekiert H. 2017. In vitro shoot cultures of pink rock-rose (*Cistus x incanus* L.)
555 as a potential source of phenolic compounds. *Acta Soc Bot Pol.* 86(4). doi:10.5586/asbp.3563.
- 556 Kuchta K, Tung NH, Ohta T, Uto T, Raekiansyah M, Grötzing K, Rausch H, Shoyama Y, Rauwald
557 HW, Morita K. 2020. The old pharmaceutical oleoresin labdanum of *Cistus creticus* L. exerts

- 550 pronounced in vitro anti-dengue virus activity. *J Ethnopharmacol.* 257:112316. doi:10.1016/j.
551 jep.2019.112316.
- 552 Li Z, Summanen PH, Komoriya T, Henning SM, Lee R-P, Carlson E, Heber D, Finegold SM. 2015.
553 Pomegranate ellagitannins stimulate growth of gut bacteria in vitro: implications for prebi-
554 otic and metabolic effects. *Anaerobe.* 34:164–168. doi:10.1016/j.anaerobe.2015.05.012.
- 555 Limmathurotsakul D, Dunachie S, Fukuda K, Feasey NA, Okeke IN, Holmes AH, Moore CE, Dolecek
556 C, van Doorn HR, Shetty N, Surveillance and Epidemiology of Drug Resistant Infections
557 Consortium (SEDRIC), et al. 2019. Improving the estimation of the global burden of antimicro-
558 bial resistant infections. *Lancet Infect Dis.* 19(11):e392–e398. doi:10.1016/
559 S1473-3099(19)30276-2.
- 560 Lipińska L, Klewicka E, Sójka M. 2014. The structure, occurrence and biological activity of ella-
561 gitannins: a general review. *Acta Sci Pol Technol Aliment.* 13(3):289–299. doi:10.17306/j.
562 afs.2014.3.7.
- 563 Liu C, Cai D, Zhang L, Tang W, Yan R, Guo H, Chen X. 2016. Identification of hydrolyzable tan-
564 nins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently
565 closed circular DNA. *Antiviral Res.* 134:97–107. doi:10.1016/j.antiviral.2016.08.026.
- 566 Liu M, Wu X, Li J, Liu L, Zhang R, Shao D, Du X. 2017. The specific anti-biofilm effect of gallic
567 acid on *Staphylococcus aureus* by regulating the expression of the *ica* operon. *Food Control.*
568 73:613–618. doi:10.1016/j.foodcont.2016.09.015.
- 569 Malode GP, Parbat AY, Shaikh AR, Panchale WA, Manwar JV, Bakal RL. 2021. Phytochemistry,
570 pharmacology and botanical aspects of *Murraya Koenigii* in the search for molecules with
571 bioactive potential-a review. *GSC Adv Res Rev.* 6(3):143–155.
- 572 Mastino PM, Marchetti M, Costa J, Usai M. 2017. Comparison of essential oils from *Cistus* spe-
573 cies growing in Sardinia. *Nat Prod Res.* 31(3):299–307. doi:10.1080/14786419.2016.1236095.
- 574 de Mello CPP, Sardoux NS, Terra L, Amorim LC, Vargas MD, da Silva GB, Castro HC, Giongo VA,
575 Madeira LF, Paixão ICNP. 2016. Aminomethylnaphthoquinones and HSV-1: in vitro and in
576 silico evaluations of potential antivirals. *Antivir Ther.* 21(6):507–515. doi:10.3851/IMP3039.
- 577 Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR. 2023. Epidemiology
578 of seasonal coronaviruses: establishing the context for the emergence of coronavirus disease
579 2019. *J Infect Dis.* 9–16.
- 580 Nicoletti M, Toniolo C, Venditti A, Bruno M, Ben Jemia M. 2015. Antioxidant activity and chem- Q6
581 ical composition of three Tunisian *Cistus*: *cistus monspeliensis* *Cistus villosus* and *Cistus li-*
582 *banotis*. *Nat Prod Res.* 29(3):223–230. doi:10.1080/14786419.2014.947486.
- 583 Pantharos P, Sukcharoen P, Phadungrakwittaya R, Akarasereenont P, Booranasubkajorn S,
584 Lumlerdkij N. 2022. Utilization of UPLC-PDA and GC–MS/MS coupled with metabolomics
585 analysis to identify bioactive metabolites in medicinal turmeric at different ages for the
586 quality assurance. *Phytomedicine.* 102:154157. doi:10.1016/j.phymed.2022.154157.
- 587 Raimundo JR, Frazão DF, Domingues JL, Quintela-Sabaris C, Dentinho TP, Anjos O, Alves M,
588 Delgado F. 2018. Neglected Mediterranean plant species are valuable resources: the example
589 of *Cistus ladanifer*. *Planta.* 248(6):1351–1364. doi:10.1007/s00425-018-2997-4.
- 590 Ravi L, Jindam D, Kumaresan S, Selvaraj V, Reddy J. 2019. Anti-methicillin resistant *Staphylococcus*
591 *aureus* potential of phytochemicals in *Terminalia catappa* and their proposed in silico mech-
592 anism of action. *Asian J Pharm Clin Res* 12(10):133–137. doi:10.22159/ajpcr.2019.v12i10.34705.
- 593 Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. 2020. Antimicrobial use, drug-resistant
594 infections and COVID-19. *Nat Rev Microbiol.* 18(8):409–410. doi:10.1038/s41579-020-0395-y.
- 595 Rebensburg S, Helfer M, Schneider M, Koppensteiner H, Eberle J, Schindler M, Gürtler L,
Brack-Werner R. 2016. Potent in vitro antiviral activity of *Cistus incanus* extract against HIV
and Filoviruses targets viral envelope proteins. *Sci Rep.* 6(1):20394. doi:10.1038/srep20394.
- Sadhu SK, Okuyama E, Fujimoto H, Ishibashi M, Yesilada E. 2006. Prostaglandin inhibitory and
antioxidant components of *Cistus laurifolius*, a Turkish medicinal plant. *J Ethnopharmacol.*
108(3):371–378. doi:10.1016/j.jep.2006.05.024.
- Salomé-Abarca LF, Mandrone M, Sanna C, Poli F, van der Hondel C, Klinkhamer PGL, Choi YH.
2020. Metabolic variation in *Cistus monspeliensis* L. ecotypes correlated to their plant-fungal
interactions. *Phytochemistry.* 176:112402. doi:10.1016/j.phytochem.2020.112402.

- 596 Singh B, Singh JP, Kaur A, Singh N. 2019. Antimicrobial potential of pomegranate peel: a review.
597 *Int J Food Sci Technol.* 54(4):959–965. doi:10.1111/ijfs.13964.
- 598 Starzec A, Włodarczyk M, Kunachowicz D, Dryś A, Kepinska M, Fecka I. 2023. Polyphenol profile
599 of *Cistus × incanus* L. and its relevance to antioxidant effect and α -glucosidase inhibition.
600 *Antioxidant.* 12(3):553. doi:10.3390/antiox12030553.
- 601 Suručić R, Travar M, Petković M, Tubić B, Stojiljković MP, Grabež M, Šavikin K, Zdunić G, Škrbić
602 R. 2021. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein
603 binding ability to ACE2 Receptor: in silico and in vitro studies. *Bioorg Chem.* 114:105145.
604 doi:10.1016/j.bioorg.2021.105145.
- 605 Thabti I, Albert Q, Philippot S, Dupire F, Westerhuis B, Fontanay S, Risler A, Kassab T, Elfalleh
606 W, Aferchichi A, et al. 2020. Advances on antiviral activity of *Morus* spp. plant extracts:
607 human coronavirus and virus-related respiratory tract infections in the spotlight. *Molecules.*
608 25(8):1876. doi:10.3390/molecules25081876.
- 609 Tito A, Colantuono A, Pirone L, Pedone E, Intartaglia D, Giamundo G, Conte I, Vitaglione P,
610 Apone F. 2021. Pomegranate peel extract as an inhibitor of SARS-CoV-2 spike binding to
611 human ACE2 receptor (in vitro): a promising source of novel antiviral drugs. *Front Chem.*
612 9:638187. doi:10.3389/fchem.2021.638187.
- 613 Tomás-Menor L, Morales-Soto A, Barraón-Catalán E, Roldán-Segura C, Segura-Carretero A, Micol
614 V. 2013. Correlation between the antibacterial activity and the composition of extracts derived
615 from various Spanish *Cistus* species. *Food Chem Toxicol.* 55:313–322. doi:10.1016/j.
616 *foodchem.2013.01.006.*
- 617 Tomasella C, Binello A, Guccione S, Cravotto G. 2022. Therapeutically valuable bioactive extracts
618 from Mediterranean plants: green technologies and molecular modelling for a viable endeavour.
619 In *Green Chemistry and Computational Chemistry*. [place unknown]: Elsevier; p. 425–448.
- 620 Tomou EM, Lytra K, Rallis S, Tzakos AG, Skaltsa H. 2022. An updated review of genus *Cistus* L.
621 since 2014: traditional uses, phytochemistry, and pharmacological properties. [place unknown]:
622 Springer. doi:10.1007/s11101-022-09827-y.
- 623 Traeder J-M. 2021. *Cistus × incanus* L. *Pandalis* is highly effective against delta variant of
624 SARS-CoV-2 in vitro. *J Dis Med Plants.* 7(3):82. doi:10.11648/j.jdmp.20210703.13.
- 625 Van de Velde F, Pirovani ME, Drago SR. 2018. Bioaccessibility analysis of anthocyanins and el-
626 lagitannins from blackberry at simulated gastrointestinal and colonic levels. *J Food Compos*
627 *Anal.* 72:22–31. doi:10.1016/j.jfca.2018.05.007.
- 628 Venditti A. 2020. What is and what should never be: artifacts, improbable phytochemicals,
629 contaminants and natural products. *Nat Prod Res.* 34(7):1014–1031. doi:10.1080/14786419.2
630 018.1543674.
- 631 Venditti A, Bianco A, Bruno M, Ben Jemia M, Nicoletti M. 2015. Phytochemical study of *Cistus*
632 *libanotis* L. *Nat Prod Res.* 29(2):189–192. doi:10.1080/14786419.2014.968569.
- 633 Viapiana A, Konopacka A, Waleron K, Wesolowski M. 2017. *Cistus incanus* L. commercial prod-
634 ucts as a good source of polyphenols in human diet. *Ind Crops Prod.* 107:297–304.
635 doi:10.1016/j.indcrop.2017.05.066.
- 636 Vignault A, Gombau J, Jourdes M, Moine V, Canals JM, Fermaud M, Roudet J, Zamora F, Teissedre
637 PL. 2020. Oenological tannins to prevent *Botrytis cinerea* damage in grapes and musts: ki-
638 netics and electrophoresis characterization of laccase. *Food Chem.* 316:126334. doi:10.1016/j.
639 *foodchem.2020.126334.*
- 640 Zalegh I, Akssira M, Bourhia M, Mellouki F, Rhallabi N, Salamatullah AM, Alkaltham MS, Khalil
641 Alyahya H, Mhand RA. 2021. A review on *cistus* sp.: phytochemical and antimicrobial activ-
642 ities. *Plants (Basel).* 10(6):1214. doi:10.3390/plants10061214.